An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

8 In the 12-week controlled period of the study, 903 patients were randomized to receive subcutaneous injections of ustekinumab (45 mg or 90 mg at weeks 0 and 4) or of high-dose etanercept (50 ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

On December 18, 2024, Celltrion announced that the FDA has approved its ustekinumab biosimilar, STEQEYMA (ustekinumab-stba), referencing Jannsen’s STELARA. STEQEYMA is approved for subcutaneous ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...